ETRA Stock Forecast: Electra Therapeutics, Inc. Price Predictions for 2026-2027
The 4 Wall Street analysts covering Electra Therapeutics, Inc. hold a median 12-month price target of $32 — +257.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 1 of 100 as at 14 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
ETRA stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Electra Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (51): Smaller than most of the companies we track.
Issuance (0): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
ETRA stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ETRA, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
The green dot is the last close — the median target sits +257.9% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Oct 2026 | Cantor Fitzgerald | Initiates | Overweight | — |
| 13 Oct 2026 | Evercore ISI Group | Initiates | Outperform | $36 |
| 13 Oct 2026 | Jefferies | Initiates | Buy | $32 |
| 13 Oct 2026 | TD Cowen | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ETRA appears on the weeks it earns a place.
ETRA analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Electra Therapeutics, Inc. (ETRA) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- —
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 32% of US stocks
Higher than 30% of US stocks
- Return on equity
- —
- Return on assets
- —
- Dividend yield
- 0.0%
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
Electra Therapeutics, Inc. (ETRA) statistics: revenue, profit & scale
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Electra Therapeutics, Inc. has a market value of $561.1M and an enterprise value of $761.7M.
forward P/E: −4.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Electra Therapeutics, Inc. employs 46 people.
Data provided by Twelve Data
ETRA vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Electra Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about ETRA stock
What is the ETRA stock price forecast for 2026-2027?
The 4 Wall Street analysts covering Electra Therapeutics, Inc. have a median 12-month price target of $32, with estimates ranging from $32 to $36. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ETRA stock a buy right now?
Of the 4 analysts covering Electra Therapeutics, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Electra Therapeutics, Inc. 1 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ETRA?
As at 14 Oct 2026, Electra Therapeutics, Inc. ranks 1 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (51 of 100).
Will ETRA stock go up?
No one can know that. What the data says: the median 12-month target from 4 analysts implies +257.9% from the last close, and Ticker Nerd's factor model ranks Electra Therapeutics, Inc. 1 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ETRA stock forecast for 2030?
No analyst covering Electra Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ETRA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $32 to $36 over the next 12 months.
What does Electra Therapeutics, Inc. do?
Electra Therapeutics Inc. is a clinical-stage biotechnology company focused on developing precision medicines for immune-mediated diseases and cancer.
About Electra Therapeutics, Inc.
Electra Therapeutics Inc. is a clinical-stage biotechnology company focused on developing precision medicines for immune-mediated diseases and cancer. The company’s programs center on signal regulatory protein, or SIRP, biology, using monoclonal antibodies designed to selectively target disease-driving immune cells while preserving normal immune function. Its lead product candidate, ipsoprubart, is being studied for secondary hemophagocytic lymphohistiocytosis, a severe hyperinflammatory condition, while additional pipeline work includes ELA822 for broader immune and inflammatory indications. Electra Therapeutics operates in the biopharmaceutical sector, where it aims to address serious disorders with limited treatment options through targeted immunology and oncology therapies. Headquartered in South San Francisco, California, the company focuses on current clinical development of novel antibody-based medicines.
CEO Dr. Quehuong Dong M.B.A., Pharm.D. · 46 employees · United States · https://electra-therapeutics.com